SCR-7952, a highly selective MAT2A inhibitor, demonstrates synergistic antitumor activities in combination with the S-adenosylmethionine-competitive or the methylthioadenosine-cooperative protein arginine methyltransferase 5 inhibitors in methylthioadenosine phosphorylase-deleted tumors

Abstract

The metabolic enzyme methionine adenosyltransferase 2A (MAT2A) was found to elicit synthetic lethality in methylthioadenosine phosphorylase (MTAP)-deleted cancers, which occur in about 15% of all cancers. Here, we described a novel MAT2A inhibitor, SCR-7952 with potent and selective antitumor effects on MTAP-deleted cancers in both in vitro and in vivo. The cryo-EM data indicated the high binding affinity and the allosteric binding site of SCR-7952 on MAT2A. Different from AG-270, SCR-7952 exhibited little influence on metabolic enzymes and did not increase the plasma levels of bilirubin. A systematic evaluation of combination between SCR-7952 and different types of protein arginine methyltransferase 5 (PRMT5) inhibitors indicated remarkable synergistic interactions between SCR-7952 and the S-adenosylmethionine-competitive or the methylthioadenosine-cooperative PRMT5 inhibitors, but not substrate-competitive ones. The mechanism was via the aggravated inhibition of PRMT5 and FANCA splicing perturbations. These results indicated that SCR-7952 could be a potential therapeutic candidate for the treatment of MTAP-deleted cancers, both monotherapy and in combination with PRMT5 inhibitors.

Keywords

drug combination / MAT2A inhibitor / MTAP-deleted cancer / PRMT5

References

[1] Zhao T, Lum JJ. Methionine cycle-dependent regulation of T cells in cancer immunity. Front Oncol. 2022; 12: 969563.

[2] Wang Z, Yip LY, Lee JHJ, et al. Methionine is a metabolic dependency of tumor-initiating cells. Nat Med. 2019; 25(5): 825-837.

[3] Guo J, Yang Y, Buettner R, Rosen ST. Targeting the methionine-methionine adenosyl transferase 2A-S-adenosyl methionine axis for cancer therapy. Curr Opin Oncol. 2022; 34(5): 546-551.

[4] Lu SC, Mato JM. S-adenosylmethionine in liver health, injury, and cancer. Physiol Rev. 2012; 92(4): 1515-1542.

[5] Attia RR, Gardner LA, Mahrous E, et al. Selective targeting of leukemic cell growth in vivo and in vitro using a gene silencing approach to diminish S-adenosylmethionine synthesis. J Biol Chem. 2008; 283(45): 30788-30795.

[6] Chen H, Xia M, Lin M, et al. Role of methionine adenosyltransferase 2A and S-adenosylmethionine in mitogen-induced growth of human colon cancer cells. Gastroenterology. 2007; 133(1): 207-218.

[7] Liu Q, Chen J, Liu L, et al. The X protein of hepatitis B virus inhibits apoptosis in hepatoma cells through enhancing the methionine adenosyltransferase 2A gene expression and reducing S-adenosylmethionine production. J Biol Chem. 2011; 286(19): 17168-17180.

[8] Zhang T, Zheng Z, Liu Y, et al. Overexpression of methionine adenosyltransferase II alpha (MAT2A) in gastric cancer and induction of cell cycle arrest and apoptosis in SGC-7901 cells by shRNA-mediated silencing of MAT2A gene. Acta Histochem. 2013; 115(1): 48-55.

[9] Bertino JR, Waud WR, Parker WB, Lubin M. Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: current strategies. Cancer Biol Ther. 2011; 11(7): 627-632.

[10] Wu Q, Schapira M, Arrowsmith CH, Barsyte-Lovejoy D. Protein arginine methylation: from enigmatic functions to therapeutic targeting. Nat Rev Drug Discov. 2021; 20(7): 509-530.

[11] Liu Q, Wu K, Zhu Y, He Y, Wu J, Liu Z. Silencing MAT2A gene by RNA interference inhibited cell growth and induced apoptosis in human hepatoma cells. Hepatol Res. 2007; 37(5): 376-388.

[12] Kalev P, Hyer ML, Gross S, et al. MAT2A inhibition blocks the growth of MTAP-deleted cancer cells by reducing PRMT5-dependent mRNA splicing and inducing DNA damage. Cancer Cell. 2021; 39(2): 209-224. e211.

[13] De Fusco C, Schimpl M, Borjesson U, et al. Fragment-based design of a potent MAT2a inhibitor and in vivo evaluation in an MTAP null xenograft model. J Med Chem. 2021; 64(10): 6814-6826.

[14] Konteatis Z, Travins J, Gross S, et al. Discovery of AG-270, a first-in-class oral MAT2A inhibitor for the treatment of tumors with homozygous MTAP deletion. J Med Chem. 2021; 64(8): 4430-4449.

[15] Zhang S, Qing L, Wang Z, et al. Design and structural optimization of methionine adenosyltransferase 2A (MAT2A) inhibitors with high in vivo potency and oral bioavailability. J Med Chem. 2023; 66(7): 4849-4867.

[16] Atkinson SJ, Bagal SK, Argyrou A, et al. Development of a series of pyrrolopyridone MAT2A inhibitors. J Med Chem. 2024; 67(6): 4541-4559.

[17] Quinlan CL, Kaiser SE, Bolanos B, et al. Targeting S-adenosylmethionine biosynthesis with a novel allosteric inhibitor of Mat2A. Nat Chem Biol. 2017; 13(7): 785-792.

[18] Shapiro SM, Bhutani VK, Johnson L. Hyperbilirubinemia and kernicterus. Clin Perinatol. 2006; 33(2): 387-410.

[19] Feustel K, Falchook GS. Protein arginine methyltransferase 5 (PRMT5) inhibitors in oncology clinical trials: a review. J Immunother Precis Oncol. 2022; 5(3): 58-67.

[20] Zhang G, Li J, Li JJ. Abstract 7603: targeting MTAP-deleted tumor via synthetic lethality with a combination of a PRMT5i and an MAT2Ai. Cancer Res. 2024; 84(6_Supplement): 7603-7603.

[21] Fischer MM, Gerrick K, Belmontes B, et al. Abstract 1644: dual inhibition of MAT2A and PRMT5 delivers synergistic anti-tumor responses in preclinical models of MTAP-deleted cancer. Cancer Res. 2023; 83(7_Supplement): 1644-1644.

[22] Shafqat N, Muniz JR, Pilka ES, et al. Insight into S-adenosylmethionine biosynthesis from the crystal structures of the human methionine adenosyltransferase catalytic and regulatory subunits. Biochem J. 2013; 452(1): 27-36.

[23] Marjon K, Cameron MJ, Quang P, et al. MTAP deletions in cancer create vulnerability to targeting of the MAT2A/PRMT5/RIOK1 axis. Cell Rep. 2016; 15(3): 574-587.

[24] Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010; 463(7283): 899-905.

[25] Mavrakis KJ, McDonald ER, Schlabach MR, et al. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5. Science. 2016; 351(6278): 1208-1213.

[26] Barekatain Y, Ackroyd JJ, Yan VC, et al. Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine. Nat Commun. 2021; 12(1): 4228.

[27] Hwang JW, Cho Y, Bae GU, Kim SN, Kim YK. Protein arginine methyltransferases: promising targets for cancer therapy. Exp Mol Med. 2021; 53(5): 788-808.

[28] Gomes Trolin C, Ekblom J, Oreland L. Regulation of methionine adenosyltransferase catalytic activity and messenger RNA in SH-SY5Y human neuroblastoma cells. Biochem Pharmacol. 1998; 55(5): 567-571.

[29] Secker KA, Bloechl B, Keppeler H, et al. MAT2A as key regulator and therapeutic target in MLLr leukemogenesis. Cancers (Basel). 2020; 12(5): 1342.

[30] Gerrick KY, Laraio J, Annen K, et al. Abstract 1637: mAT2A inhibition in MTAP-/-tumors confers mechanistic vulnerabilities to multiple clinically actionable synthetic lethal drug combinations. Cancer Res. 2023; 83(7_Supplement): 1637-1637.

[31] Moldovan GL, D’Andrea AD. How the fanconi anemia pathway guards the genome. Annu Rev Genet. 2009; 43: 223-249.

[32] Benitez A, Liu W, Palovcak A, et al. FANCA promotes DNA double-strand break repair by catalyzing single-strand annealing and strand exchange. Mol Cell. 2018; 71(4): 621-628. e624.

[33] Guo C, Wu L, Zheng X, et al. Research progress on small-molecule inhibitors of protein arginine methyltransferase 5 (PRMT5) for treating cancer. Curr Top Med Chem. 2023; 23(21): 2048-2074.

[34] Engstrom LD, Aranda R, Waters L, et al. MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer. Cancer Discov. 2023; 13(11): 2412-2431.

[35] Bedard GT, Gilaj N, Peregrina K, et al. Combined inhibition of MTAP and MAT2a mimics synthetic lethality in tumor models via PRMT5 inhibition. J Biol Chem. 2023; 300(1): 105492.

[36] Engstrom LD, Aranda R, Waters L, et al. MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer. Cancer Discov. 2023; 13(11): 2412-2431.

[37] Lv X, Xia Y, Finel M, Wu J, Ge G, Yang L. Recent progress and challenges in screening and characterization of UGT1A1 inhibitors. Acta Pharm Sin B. 2019; 9(2): 258-278.

[38] Zheng SQ, Palovcak E, Armache JP, Verba KA, Cheng Y, Agard DA. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat Methods. 2017; 14(4): 331-332.

[39] Rohou A, Grigorieff N. CTFFIND4: fast and accurate defocus estimation from electron micrographs. J Struct Biol. 2015; 192(2): 216-221.

[40] Zivanov J, Nakane T, Forsberg BO, et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. Elife. 2018; 7: e42166.

[41] Punjani A, Rubinstein JL, Fleet DJ, Brubaker MA. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat Methods. 2017; 14(3): 290-296.

[42] Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021; 596(7873): 583-589.

[43] Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004; 60(Pt 12 Pt 1): 2126-2132.

[44] Adams PD, Grosse-Kunstleve RW, Hung LW, et al. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr. 2002; 58(Pt 11): 1948-1954.

[45] Di Veroli GY, Fornari C, Wang D, et al. Combenefit: an interactive platform for the analysis and visualization of drug combinations. Bioinformatics. 2016; 32(18): 2866-2868.

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.